Invesco Pharmaceuticals ETF or First Trust Biotech Fund: Which Drug Maker-Focused Fund Should You Buy in 2026?

Invesco’s PJP fund delivered higher 5-year growth of $1,563 vs $1,480 for First Trust’s FBT, alongside a materially lower 5-year max drawdown (17.50% vs 29.90%). Costs are roughly similar (0.57% PJP vs 0.55% FBT), but the article favors PJP due to lower volatility, dividend income (PJP yield 0.90% vs FBT none), and generally comparable returns across 3/5/10-year windows. The biggest trade-off flagged is that FBT’s biotech small/mid-cap tilt contributed to higher volatility and a deeper drawdown despite stronger long-run decade performance.

Analysis

This is less a fundamental catalyst than a positioning signal: one basket is effectively a cash-flow/defensiveness factor, the other is a funding- and sentiment-sensitive innovation factor. In the current regime, that matters more than marginal fee differences; if real rates stay sticky and equity risk appetite stays mixed, the higher-beta biotech sleeve should remain mechanically disadvantaged because future cash flows are discounted harder and small/mid-cap balance sheets are more exposed to equity issuance risk.

The hidden concentration issue is that the "stable" pharma basket is not truly diversified: it inherits a lot of single-name duration from its largest obesity/weight-loss exposure. That creates a second-order risk that an LLY multiple reset would ripple through the entire ETF even if sector fundamentals stay intact. By contrast, the biotech basket has more operating leverage to a reopen in M&A and financing markets; if biotech spreads tighten and rates fall, these names can rerate faster than large-cap pharma because the base market caps are smaller and the ownership is more momentum-driven.

Near term, this is a 1-3 month flow trade, not a six-quarter structural call. The consensus appears to be rewarding lower-vol healthcare exposure, but that may be overdone if the market starts pricing a broader risk-on rotation or if FDA/M&A headlines improve sentiment for diagnostics/tools and clinical-stage platforms. The falsifier for a defensive-pharma overweight is a sustained drop in front-end yields plus biotech outperformance; the falsifier for a biotech rebound is widening credit spreads or renewed issuance pressure that forces dilution.

The better expression is relative value, not outright sector beta: own quality cash generation versus funding-sensitive innovation until macro liquidity improves. If you need convexity, wait for a better entry after a rate rally or a sector selloff; chasing the recent outperformer here likely leaves you long the wrong factor if the healthcare tape broadens.

Key Decisions for Investors

• Tactically long PJP / short FBT for the next 4-8 weeks as a defensive-vs-beta pair; stop if biotech baskets outperform by ~5% or if 10Y yields fall sharply enough to reopen duration-sensitive multiple expansion.
• Avoid adding to FBT on strength until there is evidence of cheaper biotech financing or a pickup in M&A; it has more upside torque, but only if liquidity conditions improve over the next 1-3 months.
• Treat LLY as the main idiosyncratic risk inside PJP and hedge that concentration directly if you own the ETF for defense; a put spread on LLY is a cleaner hedge than selling the whole healthcare sleeve.
• If you want a longer-dated contrarian setup, set an alert to rotate from PJP into FBT on any combination of lower rates, tighter credit spreads, and stronger biotech index breadth; that would favor the higher-beta basket over a 6-18 month horizon.
• No aggressive outright trade is warranted absent a macro/liquidity catalyst; this is currently a relative-value positioning decision rather than a high-conviction directional signal.